Hasil Pencarian - Dale N Gerding
- Menampilkan 1 - 12 hasil dari 12
-
1
-
2
-
3
-
4
Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. oleh Erik R Dubberke, Margaret A Olsen, Dustin Stwalley, Ciarán P Kelly, Dale N Gerding, Yinong Young-Xu, Cedric Mahé
Diterbitkan 2016-01-01
Artikel -
5
Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain oleh Andrew M. Skinner, Laurica Petrella, Farida Siddiqui, Susan P. Sambol, Christopher A. Gulvik, Dale N. Gerding, Curtis J. Donskey, Stuart Johnson
Diterbitkan 2020-02-01
Artikel -
6
Effect of the COVID-19 Pandemic on Rates and Epidemiology of <i>Clostridioides difficile</i> Infection in One VA Hospital oleh Lorinda M. Wright, Andrew M. Skinner, Adam Cheknis, Conor McBurney, Ling Ge, Susan M. Pacheco, David Leehey, Dale N. Gerding, Stuart Johnson
Diterbitkan 2023-07-01
Artikel -
7
-
8
Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. oleh Michelle M Merrigan, Anilrudh Venugopal, Jennifer L Roxas, Farhan Anwar, Michael J Mallozzi, Bryan A P Roxas, Dale N Gerding, V K Viswanathan, Gayatri Vedantam
Diterbitkan 2013-01-01
Artikel -
9
-
10
A simulation-based assessment of strategies to control Clostridium difficile transmission and infection. oleh Michael A Rubin, Makoto Jones, Molly Leecaster, Karim Khader, Willy Ray, Angela Huttner, Benedikt Huttner, Damon Toth, Theodore Sablay, Robert J Borotkanics, Dale N Gerding, Matthew H Samore
Diterbitkan 2013-01-01
Artikel -
11
-
12
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial oleh Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey
Diterbitkan 2022-03-01
Artikel